GlassScriptPhysician profile
Melanie A Knight
NPI 1386835718
$1,161.22
in general payments reported to CMS, 2019-2025
14 companies · $404 in 2025
The $404 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $182 · 2022: $34.13 · 2023: $360 · 2024: $182 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $434.03 | 2021-2025 | Myrisk |
| Servier Pharmaceuticals LLC | $190.57 | 2023 | |
| Merck Sharp & Dohme LLC | $132.83 | 2022-2025 | Keytruda, Welireg |
| Genentech, INC. | $129.71 | 2024 | Alecensa |
| Novartis Pharmaceuticals Corporation | $49.94 | 2025 | |
| Pfizer INC. | $39.75 | 2025 | |
| Abbvie INC. | $35.92 | 2022-2025 | |
| Incyte Corporation | $31.97 | 2021-2025 | Jakafi |
| Geron Corporation | $24.73 | 2025 | Rytelo |
| Exelixis INC. | $20.24 | 2025 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $19.62 | 2025 | Onivyde |
| Astrazeneca Pharmaceuticals LP | $18.31 | 2025 | Enhertu |
| Taiho Oncology, INC. | $17.55 | 2025 | |
| Eisai INC. | $16.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.